Dr. Wakelee on Detection of EGFR T790M Mutation in NSCLC

Heather Wakelee, MD, medical oncologist, Stanford University Medical Center, discusses a next-generation sequencing platform for the detection of non-small cell lung cancer (NSCLC) EGFR T790M mutation in urine and plasma samples, during an interview at the IASLC 17th World Conference on Lung Cancer in Vienna, Austria.

Heather Wakelee, MD, medical oncologist, Stanford University Medical Center, discusses a next-generation sequencing platform for the detection of non-small cell lung cancer (NSCLC) EGFR T790M mutation in urine and plasma samples, during an interview at the IASLC 17th World Conference on Lung Cancer in Vienna, Austria.

Wakelee discusses a study in which the researchers investigated whether a mutation enrichment next-generation sequencing could improve mutation detection in plasma and urine from the TIGER-X trial, which was a phase 1/2 study of rociletinib in patients with EGFR mutation-positive advanced NSCLC.

Of 174 matched tissue, plasma and urine specimens, 145 (83.3%) were found to be positive for the T790M mutation by central tissue testing, 142 (81.6%) of which were positive by plasma, and 139 (79.9%) positive by urine. Urine and plasma combined identified 165 cases (94.8%) as T790M-positive.

This combination of urine and plasma testing may be considered before tissue testing in EGFR TKI resistant NSCLC, including patients without extrathoracic metastases.

<<<

View more from the IASLC 17th World Conference on Lung Cancer

Related Videos
View All
Related Content